=

Apply to Flashpoint

The Program

Flashpoint works closely with founders in a startup studio where they utilize methods of behavioral economics and startup engineering to develop exceptional opportunities

Georgia Tech recognized Dr. Merrick Furst’s development of these methods with the university’s highest award for Outstanding Achievement in Research Innovation.

Operating since 2011, Flashpoint is among the most experienced startup studios in the world. It is unique in its approach. Flashpoint startups have raised over $300 million from top tier venture firms. The companies in Flashpoint’s portfolio are valued at well over $1 billion. You can learn more about how Flashpoint works in a Forbes interview (https://goo.gl/t8OYYJ) with Dr. Furst, and in an excerpt from the recently released Harvard Business Review Press book, An Everyone Culture, Becoming a Deliberately Developmental Organization (Kegan and Lahey - https://goo.gl/M7oikx).

What To Expect

Flashpoint is an Atlanta-based, four month long program, divided into two parts, and ending in demo days in several cities. The first six weeks is a concentrated on-site program, usually involving three lectures or workshops per week, weekly critiqued team presentations, weekly office hours, and a weekly speaker series, in addition to numerous interactions with potential customers. The following 10 weeks includes ongoing lectures, workshops, and office hours, but can be conducted off-site. Innovation teams from larger companies work alongside startups in the same program, for example a Coca-Cola team is in the current cohort. See this article in Forbes or this talk by founder Merrick Furst to learn about program content.


Fanancial Considerations

Flashpoint requires accepted startups to be or convert to US C- Corporations. Invited startups receive a $20k investment as a SAFE, from an independent fund (created, in part, by successful companies developed at Flashpoint.) In addition, Flashpoint purchases 7% of company stock.

Applications for Batch 8

Flashpoint’s next batch is expected to start this spring.